DUBLIN--(BUSINESS WIRE)--The "Chronic Non-healing Wounds - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Chronic Non-healing Wounds market.
A detailed picture of the Chronic Non-healing Wounds pipeline landscape is provided, which includes the disease overview and Chronic Non-healing Wounds treatment guidelines. The assessment part of the report embraces in-depth Chronic Non-healing Wounds commercial assessment and clinical assessment of the Chronic Non-healing Wounds pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Non-healing Wounds collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Chronic Non-healing Wounds with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Chronic Non-healing Wounds treatment.
- Chronic Non-healing Wounds key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Chronic Non-healing Wounds market.
Scope of the Report
- The Chronic Non-healing Wounds report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Chronic Non-healing Wounds across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Chronic Non-healing Wounds therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Chronic Non-healing Wounds research and development progress and trial details, results wherever available, are also included in the pipeline study.
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Chronic Non-healing Wounds.
Key Topics Covered
1. Report Introduction
2. Chronic Non-healing Wounds
2.3. Chronic Non-healing Wounds Symptoms
2.6. Chronic Non-healing Wounds Diagnosis
2.6.1. Diagnostic Guidelines
3. Chronic Non-healing Wounds Current Treatment Patterns
3.1. Chronic Non-healing Wounds Treatment Guidelines
4. Chronic Non-healing Wounds - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Chronic Non-healing Wounds companies collaborations, Licensing, Acquisition - Deal Value Trends
22.214.171.124. Assessment Summary
4.1.2. Chronic Non-healing Wounds Collaboration Deals
126.96.36.199. Company-Company Collaborations (Licensing / Partnering) Analysis
188.8.131.52. Company-University Collaborations (Licensing / Partnering) Analysis
184.108.40.206. Chronic Non-healing Wounds Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
220.127.116.11. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
18.104.22.168. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
22.214.171.124. Assessment by Stage and Molecule Type
5.1.5. Assessment by MoA
126.96.36.199. Assessment by Stage and MoA
5.1.6. Assessment by Target
188.8.131.52. Assessment by Stage and Target
6. Chronic Non-healing Wounds Late Stage Products (Phase-III)
7. Chronic Non-healing Wounds Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Non-healing Wounds Discontinued Products
13. Chronic Non-healing Wounds Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
184.108.40.206. Product Overview
220.127.116.11. Mechanism of action
13.1.2. Research and Development
18.104.22.168. Clinical Studies
13.1.3. Product Development Activities
22.214.171.124. Patent Detail
13.1.4. Tabulated Product Summary
126.96.36.199. General Description Table
14. Chronic Non-healing Wounds Key Companies
15. Chronic Non-healing Wounds Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Chronic Non-healing Wounds Unmet Needs
18. Chronic Non-healing Wounds Future Perspectives
19. Chronic Non-healing Wounds Analyst Review
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
- RHEACELL Gm
- Ticeba GmbH
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/7yx1ew